BR9611571B1 - composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal. - Google Patents

composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.

Info

Publication number
BR9611571B1
BR9611571B1 BRPI9611571-8A BR9611571A BR9611571B1 BR 9611571 B1 BR9611571 B1 BR 9611571B1 BR 9611571 A BR9611571 A BR 9611571A BR 9611571 B1 BR9611571 B1 BR 9611571B1
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
medicinal product
stable pharmaceutical
ngf
administration kit
Prior art date
Application number
BRPI9611571-8A
Other languages
English (en)
Other versions
BR9611571A (pt
Inventor
Young Linda R De
Xanthe M Lam
Tue Nguyen
Michael F Powell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24214304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611571(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9611571A publication Critical patent/BR9611571A/pt
Publication of BR9611571B1 publication Critical patent/BR9611571B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI9611571-8A 1995-11-07 1996-10-21 composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal. BR9611571B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468595A 1995-11-07 1995-11-07
PCT/US1996/016881 WO1997017087A1 (en) 1995-11-07 1996-10-21 Stabilizing formulation for ngf

Publications (2)

Publication Number Publication Date
BR9611571A BR9611571A (pt) 1999-03-30
BR9611571B1 true BR9611571B1 (pt) 2009-01-13

Family

ID=24214304

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9611571-8A BR9611571B1 (pt) 1995-11-07 1996-10-21 composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.

Country Status (18)

Country Link
EP (1) EP0862452B1 (pt)
JP (1) JP4057058B2 (pt)
KR (1) KR100497087B1 (pt)
CN (1) CN1126567C (pt)
AT (1) ATE255903T1 (pt)
AU (1) AU721112B2 (pt)
BR (1) BR9611571B1 (pt)
CA (1) CA2234231C (pt)
DE (1) DE69631063T2 (pt)
DK (1) DK0862452T3 (pt)
ES (1) ES2211991T3 (pt)
HK (1) HK1015261A1 (pt)
IL (1) IL124004A (pt)
MX (1) MX9803342A (pt)
PT (1) PT862452E (pt)
TR (1) TR199800811T2 (pt)
WO (1) WO1997017087A1 (pt)
ZA (1) ZA969290B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286137A1 (en) * 1997-04-11 1998-10-22 Roche Diagnostics Gmbh Ngf for the prevention of demyelination in the nervous system
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
WO2000004913A1 (en) † 1998-07-23 2000-02-03 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
WO2003000257A1 (fr) * 2001-06-26 2003-01-03 Takeda Chemical Industries, Ltd. Promoteur de production/secretion de la superfamille des tgf-$g(b)
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
EA012565B1 (ru) 2003-04-02 2009-10-30 Арес Трейдинг С.А. Жидкие фармацевтические композиции фолликулостимулирующего гормона (фсг) и лютеинизирующего гормона (лг), содержащие неионогенное поверхностно-активное вещество
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
EP1638595B1 (en) 2003-06-20 2013-03-20 Ares Trading S.A. Freeze-dried fsh / lh formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
DK3287139T3 (da) * 2015-04-21 2021-09-13 Beijing Staidson Medical Tech Co Ltd Nervevækstfaktorsammensætning og injektionspulver
WO2017117701A1 (zh) * 2016-01-04 2017-07-13 葡萄王生技股份有限公司 预防听力退化的活性物质、含其的组合物、及其制备方法
CN114252519B (zh) * 2020-09-23 2023-11-24 舒泰神（北京）生物制药股份有限公司 一种测定神经生长因子纯度的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor

Also Published As

Publication number Publication date
CN1126567C (zh) 2003-11-05
ZA969290B (en) 1998-05-05
PT862452E (pt) 2004-04-30
MX9803342A (es) 1998-09-30
TR199800811T2 (xx) 1998-07-21
BR9611571A (pt) 1999-03-30
DE69631063D1 (de) 2004-01-22
EP0862452B1 (en) 2003-12-10
CN1201394A (zh) 1998-12-09
DK0862452T3 (da) 2004-04-05
JP2002502358A (ja) 2002-01-22
CA2234231C (en) 2009-04-14
ES2211991T3 (es) 2004-07-16
JP4057058B2 (ja) 2008-03-05
ATE255903T1 (de) 2003-12-15
CA2234231A1 (en) 1997-05-15
KR100497087B1 (ko) 2005-09-09
DE69631063T2 (de) 2004-09-30
KR19990067350A (ko) 1999-08-16
HK1015261A1 (en) 1999-10-15
EP0862452A1 (en) 1998-09-09
IL124004A (en) 2003-10-31
AU721112B2 (en) 2000-06-22
WO1997017087A1 (en) 1997-05-15
AU7518696A (en) 1997-05-29

Similar Documents

Publication Publication Date Title
BR9611571B1 (pt) composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
DE69620877T2 (de) Arzneimittelformulierungen für il-12
HRP20020880B1 (en) New pharmaceutical composition
MX9709094A (es) Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina.
MY115211A (en) Novel amino acid derivatives, their preparation and use
ES2160821T3 (es) Uso de una composicion que comprende amoxicilina y acido clavulanico para la produccion de un medicamento para el tratamiento de infecciones bacterianas en pacientes pediatricos.
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
ES2174054T3 (es) Composiciones farmaceuticas acuosas liquidas que comprenden alginato sodico y bicarbonato potasico.
NO306762B1 (no) Anvendelse av lanolinderivater sammen med polyetylenglykoletere, blanding derav og transdermalt terapeutisk system
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
MX9804798A (es) Nuevos compuestos con efecto analgesico.

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/02/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.68489/2013 ORIGEM: JUIZO DA 001A VARA FEDERAL DE SAO PAULO PROCESSO NO 0017575-93.2013.4.03.6100 ACAO DE NULIDADE DE PATENTE AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: GENENTECH, INC., CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, PELE NOVA BIOTECNOLOGIA S/A E UNILEVER N.V.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 18130035057 (SP), DE 21/10/2013